FutureChem Co.,Ltd (220100.KQ)
- Previous Close
18,870.00 - Open
19,100.00 - Bid 18,910.00 x --
- Ask 18,920.00 x --
- Day's Range
18,680.00 - 19,250.00 - 52 Week Range
11,540.00 - 31,250.00 - Volume
150,282 - Avg. Volume
431,832 - Market Cap (intraday)
417.852B - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
FutureChem Co.,Ltd engages in the research and development, production, and sale of radiopharmaceuticals in South Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson's disease; Alzavue, a radiopharmaceutical for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303 and 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer's disease. FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.
www.futurechem.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 220100.KQ
View MorePerformance Overview: 220100.KQ
Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 220100.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 220100.KQ
View MoreValuation Measures
Market Cap
416.97B
Enterprise Value
387.27B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
24.12
Price/Book (mrq)
7.67
Enterprise Value/Revenue
22.39
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-54.46%
Return on Assets (ttm)
-8.03%
Return on Equity (ttm)
-15.11%
Revenue (ttm)
17.29B
Net Income Avi to Common (ttm)
-9.42B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
33.5B
Total Debt/Equity (mrq)
6.23%
Levered Free Cash Flow (ttm)
2.83B